Clinical Trial Update: Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the effects of oral migalastat hydrochloride (AT1001) in Fabry disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Migalastat hydrochloride (migalastat hydrochloride)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-10-30